Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 1 · below the Ichimoku cloud · RSI 25 (oversold) · MACD below its signal
| 2.00 | 52-week high | +173.00% |
| 1.08 | Previous month high | +47.42% |
| 0.9700 | Previous week high | +32.41% |
| 0.9200 | Previous month low | +25.58% |
| 0.8740 | Previous week low | +19.30% |
| 0.8497 | R3 (classic) | +15.98% |
| 0.8323 | R2 (classic) | +13.61% |
| 0.8150 | Previous day high | +11.25% |
| 0.8047 | R1 (classic) | +9.84% |
| 0.7873 | Pivot | +7.47% |
| 0.7700 | Previous day low | +5.11% |
| 0.7597 | S1 (classic) | +3.69% |
| 0.7423 | S2 (classic) | +1.33% |
| 0.7326 | Price now | |
| 0.7147 | S3 (classic) | −2.45% |
| 0.5500 | 52-week low | −24.92% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $797.3K | 0.00% | 693.29K | −38% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CGTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Richstone Ellen BDirector | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jun 16, 2026 | Khattar Jack ADirector | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jun 16, 2026 | Monia Brett PDirector | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jun 16, 2026 | Fletcher Aaron G.L.Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jun 16, 2026 | Wallace PeggyDirector | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Apr 15, 2026 | Ricciardi LisaChief Executive Officer | Purchase at price 1.10 per share. | 9.2K | $10.09K |
| Apr 15, 2026 | Doyle John BrendanChief Financial Officer | Purchase at price 1.13 per share. | 10K | $11.30K |
| Apr 15, 2026 | Caggiano AnthonyOfficer | Purchase at price 1.11 per share. | 10K | $11.10K |
| Feb 2, 2026 | Ricciardi LisaChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 800K | — |
| Feb 2, 2026 | Doyle John BrendanChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 200K | — |
| Feb 2, 2026 | Caggiano AnthonyOfficer | Stock Award(Grant) at price 0.00 per share. | 400K | — |
| Dec 17, 2025 | Ricciardi LisaChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Dec 17, 2025 | Doyle John BrendanChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Dec 17, 2025 | Caggiano AnthonyOfficer | Stock Award(Grant) at price 0.00 per share. | 65K | — |
| Sep 18, 2025 | Fletcher Aaron G.L.Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 0.84 per share. | 7.7K | $6.49K |
| Jul 28, 2025 | Ricciardi LisaChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Jul 28, 2025 | Doyle John BrendanChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jul 28, 2025 | Caggiano AnthonyOfficer | Stock Award(Grant) at price 0.00 per share. | 65K | — |
| Jun 17, 2025 | Richstone Ellen BDirector | Stock Award(Grant) at price 0.00 per share. | 34K | — |
| Jun 17, 2025 | Khattar Jack ADirector | Stock Award(Grant) at price 0.00 per share. | 34K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.3 | 0.0 | -30.3 | 65.8 | -6.3 | -2.5 | -22.6 | 15.7 | -6.8 | -23.7 | −45.7% | ||
| 2025 | 3.1 | -37.1 | -7.5 | 1.4 | -44.0 | 29.7 | 89.0 | 314.7 | -44.4 | 32.6 | -2.8 | -22.4 | +92.6% |
| 2024 | 22.7 | -8.8 | -12.1 | 4.9 | 2.1 | -14.9 | -39.8 | -28.9 | -34.0 | 0.6 | -14.8 | 74.4 | −62.1% |
| 2023 | -6.2 | -18.8 | 23.7 | -10.1 | 15.2 | -10.7 | -9.3 | -6.6 | -7.1 | -22.2 | -0.9 | 66.7 | −11.9% |
| 2022 | -30.4 | -30.2 | -10.4 | 0.7 | -5.4 | -19.5 | -10.4 | 8.5 | -7.3 | -6.3 | 97.2 | -40.2 | −66.8% |
| 2021 | -28.2 | -27.2 | −47.7% |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Buy / hold / sell counts